Stryker Exercises New Innovation Muscles During COVID-19
Many changes have come about for the orthopedic innovator Stryker as a result of the pandemic, says group CEO Kevin Lobo. The most important relates to methods of engagement with customers.
You may also be interested in...
Stryker is set to expand its surgical offerings after signing a $701m deal to buy Novadaq Technologies, a leading developer of fluorescence surgical imaging technology. The acquisition price is a 96% premium over Novadaq's June 16 closing price, which, according to analysts, is believed to be due to a competitive bidding process for the company.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.